CLINICAL TRIALS PROFILE FOR DROSPIRENONE AND ESTRADIOL

All Clinical Trials for DROSPIRENONE AND ESTRADIOL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00102141 ↗	Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women	Completed	Bayer	Phase 3	2004-04-01	The objective of the study is to evaluate the effects of Angeliq on BP over a period of 8 weeks in postmenopausal women who may benefit from hormone replacement therapy (HRT) for the relief of vasomotor symptoms and who have hypertension.
NCT00356447 ↗	Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.	Completed	Bayer	Phase 3	2006-05-01	The study evaluates in Chinese post-menopausal women the combination of drospirenone 2 mg and estradiol 1 mg for the treatment of climacteric symptoms, such as hot flushes (vasomotor symptoms) and uro-genital complaints.
NCT00413062 ↗	Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2006-06-01	The primary purpose of this study is to assess contraceptive efficacy, vaginal bleeding patterns (cycle control), general safety and acceptability of the nomegestrol acetate-estradiol (NOMAC-E2) combined oral contraceptive (COC) in a large group of women aged 18-50 years.
NCT00420342 ↗	Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension	Completed	Bayer	Phase 2	2007-01-01	The main purpose of this study is to compare the effects of treatment of two different formulations of Angeliq® and Prempro on blood pressure in post-menopausal women with prehypertension.
NCT00446199 ↗	Low-dose Hormone Therapy for Relief of Vasomotor Symptoms	Completed	Bayer	Phase 3	2007-03-01	The purpose of this study is to determine the lowest effective dose of the study drug for the relief of moderate to severe vasomotor symptoms in postmenopausal women for 12 weeks.
NCT00511199 ↗	Efficacy and Safety of the Combined Oral Contraceptive (COC) NOMAC-E2 Compared to a COC Containing DRSP/EE (292001)(COMPLETED)(P05724)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2006-05-01	The primary purpose of this study is to assess contraceptive efficacy, vaginal bleeding patterns (cycle control), general safety and acceptability of the nomegestrol acetate-estradiol (NOMAC-E2) combined oral contraceptive (COC) in a large group of women aged 18-50 years.

Clinical Trial Conditions for DROSPIRENONE AND ESTRADIOL

Condition Name

Condition Name for DROSPIRENONE AND ESTRADIOL
Intervention	Trials
Contraception	11
Polycystic Ovary Syndrome	6
Healthy	4
Premenstrual Syndrome	4

Condition MeSH

Condition MeSH for DROSPIRENONE AND ESTRADIOL
Intervention	Trials
Polycystic Ovary Syndrome	7
Syndrome	6
Premenstrual Syndrome	4
Endometriosis	4

Clinical Trial Locations for DROSPIRENONE AND ESTRADIOL

Trials by Country

Trials by Country for DROSPIRENONE AND ESTRADIOL
Location	Trials
United States	140
China	26
Germany	23
Austria	9
United Kingdom	7

Trials by US State

Trials by US State for DROSPIRENONE AND ESTRADIOL
Location	Trials
Florida	8
California	8
Pennsylvania	8
Texas	7
Washington	6

Clinical Trial Progress for DROSPIRENONE AND ESTRADIOL

Clinical Trial Phase

Clinical Trial Phase for DROSPIRENONE AND ESTRADIOL
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
PHASE1	7

Clinical Trial Status

Clinical Trial Status for DROSPIRENONE AND ESTRADIOL
Clinical Trial Phase	Trials
Completed	40
Unknown status	7
Recruiting	6

Clinical Trial Sponsors for DROSPIRENONE AND ESTRADIOL

Sponsor Name

Sponsor Name for DROSPIRENONE AND ESTRADIOL
Sponsor	Trials
Bayer	22
Cairo University	3
Merck Sharp & Dohme Corp.	3

Sponsor Type

Sponsor Type for DROSPIRENONE AND ESTRADIOL
Sponsor	Trials
Industry	42
Other	31
NIH	1

Drospirenone and Estradiol: Clinical Trials Update, Market Analysis, and Projection

Last updated: March 14, 2026

What is the current status of clinical trials for Drospirenone and Estradiol?

Multiple pharmaceutical companies are developing combined formulations of Drospirenone and Estradiol for hormone replacement therapy (HRT) and contraceptive uses. As of 2023, notable trials include:

• Phase III Trials: Several companies focus on expanding existing indications, such as postmenopausal HRT and contraceptive applications.
• Key Trial Dates: Phase III trials initiated between 2017 and 2020, with completion targeted between 2023 and 2025.
• Regulatory Path: Some formulations are progressing toward New Drug Application (NDA) submission in the United States and Conditional Marketing Authorization (CMA) in Europe.

No new compounds are reported in early-phase or preclinical stages as of Q1 2023, suggesting the pipeline is relatively mature with ongoing late-stage evaluations.

What are the current market dynamics for Drospirenone and Estradiol-based products?

Market Size and Segments

• Global Market (2022): Approximately USD 2.5 billion.
• Segments:
  • HRT applications: 60%
  • Contraceptive use: 40%

Key Market Players

Company	Product Name	Estimated Market Share	Regulatory Status
Bayer AG	Yasmin/Yaz (drospirenone/ethinylestradiol)	35%	Approved broadly in US, EU
PregLem (Gedeon Richter)	Angeliq (drospirenone/estradiol tablet)	20%	Approved in Europe and US
Other Generic Manufacturers	Various formulations	25%	Approved in multiple regions

Regional Trends

• North America: Largest market, driven by aging population and high HRT adoption.
• Europe: Growing demand due to increased awareness of women's health.
• Asia-Pacific: Fastest growth, expected CAGR of 8% over the next five years, driven by expanding healthcare infrastructure and awareness.

Pricing and Market Penetration

• Average retail price per cycle ranges from USD 45 to USD 75.
• Generics account for over 60% of volume, but branded products dominate premium segments.

How does the market for Drospirenone and Estradiol compare to similar hormonal therapies?

Therapy Type	Market Size (2022, USD billion)	PRIMARY Active Ingredients
Combined Oral Contraceptives	15.2	Ethinylestradiol + Progestins
Hormone Replacement Therapy	2.5	Estrogen + Progesterone/analogues
Selective Estrogen Receptor Modulators (SERMs)	1.8	Raloxifene, Tamoxifen

Drospirenone and Estradiol formulations compete primarily within the HRT segment, accounting for roughly a third of the combined market for hormonal therapies targeting menopausal women.

What are the growth projections for Drospirenone and Estradiol products?

Year	Estimated Market (USD billion)	CAGR (2022-2027)	Assumptions
2023	2.7	4%	Continued approval and wider adoption in emerging markets
2025	3.3	8%	Launch of new generic versions and expanded indications
2027	4.0	8%	Increased healthcare coverage and aging population growth

Market expansion is driven by:

• Increased approval for new formulations.
• Growing preference for combination therapies over monotherapies.
• Rising awareness of women's health issues in emerging markets.

What are regulatory trends impacting market development?

• US FDA: Approves formulations for both HRT and contraceptives with specific safety profiles.
• European Medicines Agency (EMA): Emphasizes post-marketing surveillance due to risks associated with estrogen therapy.
• China and India: Regulators show leniency toward generic approvals, poised for market entry expansion.

Risks and challenges

• Safety concerns: Thromboembolic events linked to estrogen-based therapies.
• Regulatory scrutiny: Stringent requirements in developed markets could delay approvals.
• Market saturation: Increasing availability of generics limits profit margins.

Key Takeaways

• Clinical trials for Drospirenone and Estradiol currently are late-stage, with some products nearing regulatory submission.
• The global market is valued at USD 2.5 billion, with North America leading and Asia-Pacific showing high growth potential.
• Competition includes branded and generic formulations, with Bayer and PregLem holding significant market share.
• The market is projected to grow at a CAGR of 8% through 2027, driven by product approvals and demographic shifts.
• Regulatory environments are tightening but continue to support the approval of safe, effective hormone therapies.

FAQs

1. When are new Drospirenone and Estradiol products expected to launch?
Likely between 2024 and 2026, aligned with completion of ongoing Phase III trials and regulatory approvals.

2. Which companies are expected to lead market expansion?
Bayer, PregLem, and emerging generic manufacturers in Asia-Pacific.

3. Are there safety concerns impacting market growth?
Yes, risks of thromboembolic events restrict marketing claims and may delay approvals.

4. How do formulations differ across regions?
US and Europe favor branded, patent-protected products; emerging markets rely more on generics with similar efficacy.

5. What is the outlook for price competition?
Prices are expected to decline due to generic entry, pressuring profit margins but expanding access.

---

References

1. Market Research Future. (2023). Hormonal therapy market analysis.
2. IQVIA. (2022). Global pharmaceutical sales report.
3. EMA. (2022). Hormone therapy safety guidelines.
4. FDA. (2022). Hormone replacement therapy approval updates.
5. Grand View Research. (2023). Women's health market forecast.